SCHEDULE 13G/A: 3i LP Files Exit Schedule 13G for BriaCell Therapeutics, Reducing Stake Below 5%

3i, LP, along with 3i Management LLC and Maier Joshua Tarlow, has filed an Amendment No. 1 to Schedule 13G, indicating they are no longer beneficial owners of more than 5% of BriaCell Therapeutics Corp.'s common shares.

Summary

• The filing is an Amendment No. 1 to Schedule 13G for BriaCell Therapeutics Corp. (CUSIP: 107930208).
• The reporting persons are 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, who have filed jointly.
• The filing constitutes an 'exit filing,' meaning the reporting persons have ceased to be beneficial owners of more than 5% of BriaCell Therapeutics Corp.'s outstanding common shares.
• As of March 31, 2025, the reporting persons collectively beneficially owned 190,006 common shares, representing 4.9% of the class.
• This ownership includes 91,695 Common Shares held directly by 3i, LP, and up to 98,311 Common Shares issuable upon the exercise of warrants, subject to a 4.99% beneficial ownership limitation ('Blocker').
• The percentage is based on 3,709,440 common shares outstanding as of March 31, 2025, as disclosed in the issuer's Form 10-Q (March 12, 2025) and Form S-1 (April 22, 2025).

Sentiment

Score: 5

Explanation: The document is a factual disclosure of a change in beneficial ownership, specifically an exit filing. It does not contain positive or negative operational or financial news about the issuer, making the sentiment neutral. The reduction in stake by a significant holder could be interpreted neutrally or slightly negatively depending on market perception, but the filing itself is purely informational.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of a change in beneficial ownership, indicating that a specific investment entity has reduced its stake in BriaCell Therapeutics Corp. below the 5% reporting threshold. It does not provide insights into broader industry trends or the company's competitive position, but rather reflects a portfolio management decision by the reporting entity.

Stakeholder Impact

• For shareholders of BriaCell Therapeutics Corp., this indicates that 3i, LP and its affiliates are no longer a significant beneficial owner (below 5%), which could be interpreted as a rebalancing of their portfolio or a change in investment strategy regarding BriaCell.

Key Dates

Keywords

BriaCell Therapeutics Corp., Schedule 13G, Beneficial Ownership, Exit Filing, 3i LP, Common Shares, SEC Filing, Investment Management